Linerixibat - ≥99% , Ileal bile acid transporter inhibitor, CAS No.1345982-69-5, Ileal bile acid transporter inhibitor
Disponible
SKU
L648859
Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC 50 of 42 nM human ASBT . Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment
In Vitro
The zwitterionic, nonhygroscopic, crystalline salt form of Linerixibat (Compound 56) shows good aqueous solubility at pH 7.4 (>7 mg/mL), excellent thermal stability, and did not generate reactive or humanspecific metabolite, characteristics. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Linerixibat (GSK2330672; 0.05-10 mg/kg; oral gavage; twice daily; for 14 days; male ZDF rat) treatment lowers glucose in an animal model of type 2 diabetes . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Zucker Diabetic Fatty (ZDF) rat Dosage: 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg Administration: Oral gavage; twice daily; for 14 days Result: Led to a 1.30-1.64% reduction in hemoglobin A1c (HbA1c), a greater than 50% reduction in nonfasted plasma glucose to below 200 mg/dL, and statistically significant higher plasma insulin.
Form:Solid
IC50& Target:IC50: 42 nM (Apical sodium-dependent bile acid transporter (ASBT))
Más Información
| CAS | 1345982-69-5 |
|---|---|
| Sinónimos | 1-(2,5-Dimethoxy-phenylazo)-2-naphthol | GSK 2330672 | Pentanedioic acid, 3-[[[(3R,5R)-3-butyl-3-ethyl-2,3,4,5-tetrahydro-7-methoxy-1,1-dioxido-5-phenyl-1,4-benzothiazepin-8-yl]methyl]amino]- | WHO 10729 | 2-Methyl-1,4-benzenediamine sulfate (1:1) | MFCD2 |
| Especificaciones y pureza | ≥99% |
| Condiciones de almacenamiento de almacenamiento | Store at -20°C |
| Enviado en | Ice chest + Ice pads |
| Product Description | Linerixibat (GSK2330672) is a highly potent, nonabsorbable and orally active apical sodium-dependent bile acid transporter (ASBT) inhibitor with an IC 50 of 42 nM human ASBT . Linerixibat can be used as lipid-lowering agent. Linerixibat has the potential for type 2 diabetes and Primary Biliary Cholangitis treatment In Vitro The zwitterionic, nonhygroscopic, crystalline salt form of Linerixibat (Compound 56) shows good aqueous solubility at pH 7.4 (>7 mg/mL), excellent thermal stability, and did not generate reactive or humanspecific metabolite, characteristics. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Linerixibat (GSK2330672; 0.05-10 mg/kg; oral gavage; twice daily; for 14 days; male ZDF rat) treatment lowers glucose in an animal model of type 2 diabetes . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Zucker Diabetic Fatty (ZDF) rat Dosage: 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg Administration: Oral gavage; twice daily; for 14 days Result: Led to a 1.30-1.64% reduction in hemoglobin A1c (HbA1c), a greater than 50% reduction in nonfasted plasma glucose to below 200 mg/dL, and statistically significant higher plasma insulin. Form:Solid IC50& Target:IC50: 42 nM (Apical sodium-dependent bile acid transporter (ASBT)) |
| Solubilidad | DMSO : 50 mg/mL (91.46 mM; Need ultrasonic) |
| Objetivo | SLC10A2 |
| PubChem CID | 53492727 |
| Fórmula molecular | C28H38N2O7S |
Reseñas
Reseñas de cliente
Remind me later